entertainment -WSS

entertainment

author：hotspot 2025-10-01 01:49:13 - browse：4

a person wearing blue dress conducts a finger prick test on another person in a home setting — coverage from STAT — Adobe

The last decade has seen billions of dollars flow into digital health companies that promise to improve outcomes for the 38 million Americans living with type 2 diabetes. Their products aren’t cheap, but in the long term, they pitch to health plans and employers that these digital tools will help cut health care costs by preventing serious complications like amputation and kidney failure.

A systematic review by the Peterson Health Technology Institute found, though, that digital tools used to manage diabetes with the help of finger-stick blood glucose readings don’t result in clinically meaningful improvements over standard care. As a result, they don’t reduce health care spending — they drive it up.

“Most of the solutions in this category do not deliver clinical benefits that justify their cost,” Caroline Pearson, executive director of the institute, told STAT. Despite finding that some populations may benefit, the report concludes that current evidence doesn’t support broader adoption for most products.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： CDC marks new Covid

WSS

Change Healthcare cyberattack prompts Medicare loan program

With Wegovy coverage, Medicare patients may face high costs

The problem with charging patients to message their doctors

Headspace, Meta partner to launch VR meditation app for Quest

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

Wikipedia

entertainment

focus

How one medical school became remarkably diverse

NEJM study link tiny plastics in blood vessels to heart problems

What does generative AI mean for health care? We asked experts

Testing GLP

Anesthesiologist group: stop taking Ozempic before surgery

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

Hepatitis C has a cure — but many Americans still lack access to it

U.K. officials, researchers try to ease path for bespoke genetic treatments

Trump demands the U.S. pay no more for drugs than other countries … again

Readout LOUD podcast, live from the STAT Breakthrough Summit East

entertainment

IVF, abortion rights issues kick off Biden’s State of the Union

Yancopoulos of Regeneron works to expand Dupixent success

Cancer, immunology, HIV research ensnared in fetal tissue politics

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Sen. Paul opposes bill to ban Chinese biotechs

A deep dive into Applied Therapeutics’ data, and questions on Cassava

hotspot

knowledge

explore

leisure time